Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Simic, B; Mocharla, P; Crucet, M; Osto, E; Kratzer, A; Stivala, S; Kühnast, S; Speer, T; Doycheva, P; Princen, HM; van, der, Hoorn, JW; Jukema, JW; Giral, H; Tailleux, A; Landmesser, U; Staels, B; Lüscher, TF.
Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
Atherosclerosis. 2017; 257:186-194 Doi: 10.1016/j.atherosclerosis.2017.01.011
Web of Science PubMed FullText FullText_MUG

 

Co-authors Med Uni Graz

Kratzer Adelheid

Osto Elena

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

BACKGROUND AND AIMS: High-density lipoprotein cholesterol (HDL-C) is inversely related to cardiovascular risk. HDL-C raising ester transfer protein (CETP) inhibitors, are novel therapeutics. We studied the effects of CETP inhibitors anacetrapib and evacetrapib on triglycerides, cholesterol and lipoproteins, cholesterol efflux, paraoxonase activity (PON-1), reactive oxygen species (ROS), and endothelial function in E3L and E3L.CETP mice. METHODS: Triglycerides and cholesterol were measured at weeks 5, 14 and 21 in E3L.CETP mice on high cholesterol diet and treated with anacetrapib (3 mg/kg/day), evacetrapib (3 mg/kg/day) or placebo. Cholesterol efflux was assessed ex-vivo in mice treated with CETP inhibitors for 3 weeks on a normal chow diet. Endothelial function was analyzed at week 21 in isolated aortic rings, and serum lipoproteins assessed by fast-performance liquid chromatography. RESULTS: Anacetrapib and evacetrapib increased HDL-C levels (5- and 3.4-fold, resp.) and reduced triglycerides (-39% vs. placebo, p = 0.0174). Total cholesterol levels were reduced only in anacetrapib-treated mice (-32%, p = 0.0386). Cholesterol efflux and PON-1 activity (+45% and +35% vs. control, p < 0.005, resp.) were increased, while aortic ROS production was reduced with evacetrapib (-49% vs. control, p = 0.020). Anacetrapib, but not evacetrapib, impaired endothelium dependent vasorelaxation (p < 0.05). In contrast, no such effects were observed in E3L mice for all parameters tested. CONCLUSIONS: Notwithstanding a marked rise in HDL-C, evacetrapib did not improve endothelial function, while anacetrapib impaired it, suggesting that CETP inhibition does not provide vascular protection. Anacetrapib exerts unfavorable endothelial effects beyond CETP inhibition, which may explain the neutral results of large clinical trials in spite of increased HDL-C.

Find related publications in this database (using NLM MeSH Indexing)

Animals - administration & dosage

Anticholesteremic Agents - pharmacology, toxicity

Apolipoprotein E3 - genetics

Aryldialkylphosphatase - blood

Benzodiazepines - pharmacology, toxicity

Biomarkers - blood

Cholesterol Ester Transfer Proteins - antagonists & inhibitors, genetics, metabolism

Cholesterol, HDL - blood

Diet, High-Fat - administration & dosage

Disease Models, Animal - administration & dosage

Dyslipidemias - blood, drug therapy, genetics, physiopathology

Endothelium, Vascular - drug effects, metabolism, physiopathology

Female - administration & dosage

Genetic Predisposition to Disease - administration & dosage

Humans - administration & dosage

Mice, Transgenic - administration & dosage

Oxazolidinones - pharmacology, toxicity

Phenotype - administration & dosage

Reactive Oxygen Species - metabolism

Triglycerides - blood

Up-Regulation - administration & dosage

Vasodilation - drug effects

Find related publications in this database (Keywords)

CETP

Hyperlipidemia

Endothelial dysfunction

HDL-Cholesterol

© Med Uni Graz • Imprint